Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A phase 3 trial shows cabazitaxel improves overall and progression-free survival in men with advanced multi-drug resistant prostate cancer. The medication was found to be effective in patients whose disease progressed after standard chemotherapy with docetaxel.
A recent study by Mayo Clinic found that radical prostatectomy significantly improves survival rates for men with localized prostate cancer. The procedure has led to excellent overall survival rates, with only 3% of patients dying from prostate cancer.
Researchers have developed a biomarker panel that distinguishes prostate cancer from benign prostate disease and healthy tissue with high accuracy. The panel uses autoantibodies to identify proteins on the surface of cancer cells, enabling early diagnosis and potentially increasing cure rates.
Researchers found that surgery provides high survival rates of 92% for patients with aggressive prostate cancer, outperforming radiation therapy alone in terms of cancer-specific and overall survival. The study suggests that limiting hormone therapy may avoid adverse health consequences for these patients.
Researchers at St. Michael's Hospital discovered that the cholesterol-lowering drug Crestor suppressed human prostate cancer cells grown in mice. This pre-clinical evidence suggests statins could be an effective treatment for prostate cancer, potentially offering a safer alternative to existing therapies.
A study of 43,987 men aged 55-74 found that those with low PSA levels did not have a significant reduction in prostate cancer deaths. Men with high PSA levels benefited more from screening and treatment. The results suggest that aggressive follow-up testing and treatment may not be beneficial for men with low PSA values.
A new analysis found that prostate cancer treatment choices significantly impact long-term care costs. Watchful waiting had the lowest initial and five-year total costs, while hormonal therapy plus radiation and surgery were associated with higher costs.
Brothers of men with prostate cancer are at a higher risk of diagnosis due to increased diagnostic activities, not genetic mutations. Incidence is highest among men with two brothers diagnosed, and detection bias contributes significantly.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
Researchers developed a method to accurately assess prostate cancer severity by analyzing magnetic resonance images and spectra. This technique has shown over 90% accuracy in distinguishing low-grade from high-grade prostate cancers, which could lead to better patient management and cost savings.
Researchers at McGill University have discovered that the facultative enzyme Mnk plays a key role in developing prostate cancer. By blocking Mnk's activity, mice became resistant to prostate cancer growth, offering hope for targeted treatments.
A new study led by researchers at UCSF found that surgery is more effective than radiation and hormone therapies for men with high-risk prostate cancer. The study analyzed data from 7,538 men with localized disease and found a significant difference in survival rates between surgical removal of the prostate and other treatment options.
A pilot study published in the Journal of Endourology suggests that CO2 laser technology used with robotic prostate cancer surgery may preserve sensitive nerve areas necessary for erections and urinary continence. The technology, known as BeamPath, was found to be easy to manipulate and accurate.
A Purdue University-led team has found a molecular compound that appears to be useful in identifying cancerous and precancerous tissue in the prostate. The compound, cholesterol sulfate, is absent in healthy prostate tissue but present in prostate cancer tumors, making it a potential marker for the disease.
Researchers identified basal cells from benign prostate tissue as a new cell-of-origin for human prostate cancer. This discovery could lead to better predictive and diagnostic tools, as well as the development of targeted treatments. The study provides a novel model system for understanding prostate cancer development and progression.
Researchers found that prostate basal cells can spawn tumors in the prostate gland, providing a new originator of prostate cancer. The study used human prostate tissue samples to develop new techniques and identified unique cell surface markers to distinguish luminal cells from basal cells.
A study found that men with low-risk prostate cancer often receive aggressive treatment, including surgery or radiation, even if their PSA levels are low. The researchers suggest that lowering the biopsy threshold for men with PSA levels below 4 nanograms per milliliter could lead to an increase in unnecessary treatments.
UT Southwestern researchers found blocking a specific enzyme step can halt tumor growth. The study suggests this approach may provide new therapy options for patients with end-stage prostate cancer, which has limited treatment choices.
A high-fat diet is found to activate nuclear factor kappa B (NF-κB) in the prostate, leading to inflammation, oxidative stress, and proliferation. The study provides direct evidence of a link between a high-fat diet and an increased risk of benign prostatic hyperplasia, prostatitis, and prostate cancer.
Gene therapy holds promise in treating prostate cancer, but challenges remain in achieving effective treatment. Researchers call for better testing systems and innovative approaches to advance the field. Prostate cancer is a leading cause of cancer death among men in the US.
Researchers found that men with high-risk prostate cancer lose significantly less bone mineral content as they age compared to healthy men. The study, published in BJUI, suggests a possible link between prostate cancer and bone health, which could lead to new prevention strategies.
Researchers found that sulforaphane, a broccoli compound, reduces prostate cancer risk by affecting cells lacking the PTEN gene. In these cells, sulforaphane inhibits tumor growth and competitiveness. This study suggests potential therapeutic applications of sulforaphane.
Researchers have identified a functional DNA element associated with prostate cancer risk, revealing new insights into the molecular mechanisms of the disease. The study found that variants in this region can alter the expression of critical genes, increasing disease risk.
A genetic variant associated with increased expression of oncogene MYC has been identified in a gene desert, increasing prostate cancer risk. The study showcases a new protocol for studying cancer-risk variants in gene deserts and highlights the importance of regulatory sequences in controlling gene expression.
Researchers found that men with a baseline PSA of less than 4 had a very low risk of death from prostate cancer, while those with scores of 10 or higher were 11 times more likely to die. The study suggests routine screening among healthy men with normal life expectancy can help identify high-risk patients and save lives.
A recent study by UNC researchers provides evidence that a specific gene, MAGE-11, interacts with proteins to promote androgen receptor activity in advanced prostate cancer cells. This finding opens the door to additional targets for new therapies and broader clinical applications of new drugs.
Researchers developed a groundbreaking laboratory model of hormone-induced human prostate cancer initiation and progression, offering new insights into the disease's hormonal mechanisms. The model enables the study of cancer development from normal tissue to initiation and progression, facilitating preventive therapy testing and accele...
A 14-year randomized controlled trial shows that prostate cancer screening significantly reduces mortality rates. The study found that men screened for prostate-specific antigen (PSA) had a lower risk of dying from prostate cancer compared to those not screened.
A comprehensive genomic analysis of prostate cancer has identified key alterations in the androgen receptor pathway and defined subsets of low- and high-risk disease. The study provides valuable resources for cancer research and may lead to the creation of a genetic-based test to determine which tumors require aggressive treatment.
Researchers found that optimal brachytherapy dose on the same day as implant reduces relapse risk by 20 percentage points, achieving cure in 94.4% of patients. Calculating radiation dose on implant day allows for immediate adjustments to ensure treatment efficacy.
Researchers found significant association between chlordecone exposure and prostate cancer risk, with higher risk seen in individuals with family history or exposure to Western lifestyle. Genetic susceptibility factors may play a role in this relationship.
A new study found that active surveillance is a suitable treatment option for patients with low-risk prostate cancer, resulting in lower mortality rates compared to radical prostatectomy or radiation therapy. After a median follow-up of 8.2 years, the surveillance group had a higher percentage of deaths from competing causes.
Researchers found that polyphenols in red wine and green tea inhibit cancer growth by disrupting the sphingosine kinase-1 survival pathway. This discovery could lead to the development of drugs targeting this pathway to stop or slow prostate cancer progression, improving current treatments.
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center present several studies at the 2010 American Urological Meeting, including a potential breakthrough in using 5-alpha reductase inhibitors to improve PSA test accuracy for prostate cancer diagnosis. Additionally, they present results on robotic surgery ...
A new ultrasensitive PSA test using nanoparticle technology can detect low levels of PSA in the blood that indicate cancer recurrence. The test may provide early and more accurate answers, allowing doctors to act at the earliest and most sensitive time for patients' long-term survival.
Researchers found thymoquinone induces oxidative stress in prostate cancer cells, leading to increased cell death and decreased tumor growth. The study suggests a new potential treatment option for highly aggressive prostate cancers.
A study published in Cancer Research found that high calcium intake, even from non-dairy sources such as soy and green vegetables, may increase prostate cancer risk in Chinese men. The research, which analyzed data from over 27,000 men, showed a 25% increased risk of prostate cancer among those consuming higher amounts of calcium.
Men who choose radiotherapy over surgery for prostate cancer have a 17% improvement in overall survival rate, with patients refusing treatment having a 51% 10-year survival rate. This study highlights the importance of considering treatment options when diagnosed with prostate cancer.
The REDUCE trial found dutasteride to be effective in reducing the chance of a positive biopsy by 23% and preventing disease progression. However, more detailed analyses are needed to monitor long-term effects on cardiovascular health and selectively identify aggressive disease.
A recent study by S. Eggener et al. discusses the significance and impact of focal therapy for low-risk prostate cancer patients, highlighting its potential as an alternative to whole-gland treatment. The study reviews patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for focal therapy.
A new study found that gene fusions are a specific 'bad actor' in prostate cancer and should be targeted by treatments, rather than the androgen receptor. The research suggests that blocking these fusions can prevent normal prostate cell development, allowing cancer to develop.
A new study by researchers found that measuring bone density before starting ADT can help prevent fractures and reduce costs. Another study suggests that CTCA can identify patients who need more invasive testing for heart disease.
A study found that preoperative MRI can help surgeons identify the neurovascular bundle and spare it during RALP, leading to better erectile function outcomes. The technique has improved surgical decision-making without compromising oncological results.
A new study examines the safety and tolerance of SE5-OH containing Natural S-equol in healthy adult Japanese men, with results showing normal hormone levels and PSA levels. The supplement appears to be well-tolerated, but further studies are needed to confirm its effects on prostate health.
Researchers found that men with multiple affected relatives have a substantially increased risk of developing prostate cancer. The study suggests that doctors should urgently recommend early detection screenings for men with several affected relatives, particularly if they have been diagnosed at a young age.
The EAU Congress ended its 25th anniversary meeting in Barcelona with awards for outstanding research in urology. Despite volcanic eruptions disrupting travel plans, the congress proceeded and recognized excellence in cancer and non-cancer research.
Researchers found strong correlation between colder weather, low rainfall, and higher prostate cancer rates in the US. The study suggests that persistent organic pollutants may be to blame, with cold weather slowing their degradation.
A new study suggests that high estrogen levels in men may increase their risk of developing prostate cancer. However, the researchers also found that certain estrogen metabolites may offer a protective benefit against prostate cancer development.
A blood test and DNA analysis accurately predict which men with low-grade prostate cancers may need treatment, say Johns Hopkins scientists. The prostate health index and DNA content in biopsy tissue can detect the progression of small prostate cancers.
A recent study published in Johns Hopkins Medicine found that men who gained five or more pounds near the time of their prostate surgery are twice as likely to have a recurrence of their cancer compared with patients whose weight is stable. Physical activity was shown to reduce this risk.
Researchers have evaluated a blood test that identifies patients with low-grade, low-stage prostate cancer who are at risk of needing treatment. The study found that a biomarker called Prostate Health Index was significant in predicting unfavorable biopsy conversion.
The study demonstrates a potential new treatment paradigm in oncology with improved overall survival rates for metastatic castration-resistant prostate cancer patients. The treatment, Sipuleucel-T, was shown to have well-balanced prognostic factors and mild adverse events.
The European Association of Urology does not recommend mass screening for prostate cancer in Europe, citing the risk of overdiagnosis and overtreatment. Men should be properly informed by their physician about the pros and cons of screening, such as a PSA test.
The European Association of Urology (EAU) has launched new and updated clinical guidelines for urological conditions, including muscle-invasive and metastatic bladder cancer and prostate cancer. The guidelines provide evidence-based recommendations on diagnosis, staging, treatment options, and follow-up care.
A new multicenter study has found that MDV3100 is safe and effective for patients with castration-resistant prostate cancer. The drug slowed tumor growth, reduced PSA levels, and stabilized disease progression, offering new hope for patients with limited treatment options.
A study published in The Lancet Oncology found that men with prostate cancer are at increased risk of potentially life-threatening blood clots. Patients receiving endocrine therapy had the highest risk, especially younger men and those with advanced disease.
Researchers at Emory University have successfully developed a clinical test for XMRV, a retrovirus linked to prostate cancer, using neutralizing antibody assay technology. The test has been confirmed by two independent labs and technologies, providing confidence in its accuracy.
A new study found that certain HIV drugs can inhibit a retrovirus linked to prostate cancer and chronic fatigue syndrome. Raltegravir and other antiviral medications showed effective virus replication inhibition, suggesting possible treatments for these devastating illnesses.
Researchers found that four HIV anti-drugs inhibit XMRV replication, potentially offering a new treatment for prostate cancer and chronic fatigue syndrome. Combination therapies may also delay or prevent the virus from mutating into drug-resistant forms.
A four-year international trial found that dutasteride reduced the chances of being diagnosed with mid-range aggressiveness tumors, which account for most prostate cancers. The drug was effective at reducing the risk of medium-grade tumors by 31.4% in men with a family history of prostate cancer.